Information Provided By: 
Fly News Breaks for April 1, 2015
AMRN
Apr 1, 2015 | 08:00 EDT
SunTrust lowered its estimate for Q1 sales of Amarin's Vascepa drug to $16.5M from $17.8M, as the firm says that the current prescription rate is tracking slightly below its expectations, while winter storms negatively affected uptake of the drug in the first two months of the quarter. However, given what the firm sees as limited competition and the drug's attractive formulary position and pricing, it still expects 2015 sales of the drug to come in slightly above the consensus outlook. It reiterates a $6 price target and Buy rating on the shares.
News For AMRN From the Last 2 Days
There are no results for your query AMRN
